Ivf market trends and an overview

13,077 views
12,648 views

Published on

Published in: Health & Medicine

Ivf market trends and an overview

  1. 1. FLOW OF THE PRESENTATIONAssisted reproductive technologies (ART)Success rate of ART MethodsIVF - InVitro Fertilization An OverviewIVF Treatment PlanIVF Cost AspectsFertility treatments Cost AspectsFertility treatments Cost COMPARISON ACROSS GLOBEDrugs usually prescribed in IVF TreatmentTop 10 Players in Indian IVF Segment Market & Emerging Players in IVF MarketINDIA IVF Market Overview ,Market Trends & PotentialRegulatory Aspects for IVF in IndiaTHE ASSISTED REPRODUCTIVE TECHNOLOGIES (REGULATION) BILL – 2010Regulatory Aspects for IVF across globe and comparisonThe factors affecting IVF Market in India and across globeRecommendations & Suggestions
  2. 2. ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) Commonly used method in %Assisted reproductive technologies (ART) refer to infertility treatments that involve the handling of eggs or embryos.This includes IVF, GIFT, and ZIFT. ZIFT (Zygote Intra 3With GIFT (gamete intrafallopian Fallopian Transfer) transfer), the egg and sperm, or gametes, are not fertilized outside the body. Instead, they are placed GIFT (Gamete Intra Commonly used 2 Fallopian Transfer) method in % together into one of the womans fallopian tubesZIFT: With ZIFT (zygote intrafallopian IVF ( In Vitro 1 Fertilization ) transfer), the zygote is placed in one of the fallopian tubes. This is usually done via laparoscopic 0 20 40 60 80 surgery.
  3. 3. SUCCESS RATE OF ART METHODS Live birth rate of each IVF Cycle For women under age 35, the live birth rate Rate in % for each IVF cycle is 30% to 35%. For women ages 35 to 37, the rate is 25%. 35 For women ages 38 to 40, the rate is 15% to 20%, 30 For women over age 40, the success rate is 6% to 10%. 25 ART is also sometimes performed with donor eggs and/or sperm. For women whose eggs are of lower 20 quality, donor eggs may be the best option. Live birth rate of 15 each IVF Cycle Rate The live birth rate for egg donation is in % between 40% to 45%, but less than 10% of couples choose to use donor 10 eggs or sperm. 5 0 <35 35-37 38-40 > 40 1 2 3 4
  4. 4. IVF - INVITRO FERTILIZATION AN OVERVIEWWhat Is IVF?IVF stands for in vitro fertilization, which literally means "in lab conception." With IVF treatment, the egg is fertilized with sperm in a petri dish. Typically, many eggs are retrieved from the biological mother (who may or may not be the intended parent), as not every egg will fertilize, and not every fertilized egg will become a viable embryo.Indications: Bilateral blocked Fallopian tubes Severe endometriosis Pelvic inflammatory disease with severe adhesion Premature Menopause Failed reversal of Vasectomy/ Tubectomy Obstructive azoospermia Genetic diseases Menopause Surrogacy (Traditional/ Gestational)
  5. 5. CRYOPRESERVATIONA few days after fertilization, the best embryo or embryos are transferred to the mother or surrogates uterus via a catheter through the cervix. Any extra embryos may be cryopreserved for future cycles.
  6. 6. IVF TREATMENT PLANIVF- Treatment Plan• Day 1 . Inj Lupride, 0.2 ml sc. ( Downregulation starts)Day 2 . Inj Lupride, 0.2 ml sc.Day 3 . Inj Lupride, 0.2 ml sc.• Vaginal ultrasound scan to confirm there is no ovarian cyst. If there is no cyst, we can commence superovulation.• If there is a cyst, we aspirate/ puncture it under ultrasound guidance and continue with the treatment.Day 4 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IM. Superovulation starts.Day 5 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IMDay 6 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IMDay 7 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IMDay 8 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IMDay 9 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IMDay 10 . Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IM.Vaginal ultrasound scan to monitor follicular growthThe Lupride and Menogon injections will continue on a daily basis;and scans will be performed every alternate day, until the follicles are mature.This is usually Day 14- Day 16 for most patients. At this time, an HCG injection will be given, and eggs retrieved 36 hours after this.Embryo transfer is performed 3 days later; and supernumerary embryos, if any, are cryopreserved.After the transfer, luteal phase support is provided with daily Progynova ( estradiol valerate2 mg, 3 tab daily; and Uterogestan ( 200 mg), 6 vaginalsuppositories daily.You can travel back 3 days after the embryo transfer.14 days after the transfer, you need to do a blood test for beta HCG to confirm a pregnancy
  7. 7. IVF COSTWhat Does IVF Cost?The average cost for IVF is $12,000, but this can vary depending,on what technologies are being used. IVF with egg donation is the most costly, withone cycle being anywhere from $25,000 to $30,000.
  8. 8. FERTILITY TREATMENTS COST ASPECTS Sr. No. Activities for Infertility Treatment INR USD $ 1 Consultation 5000-10000 20 2 Semen Analysis 200 - 500 10 3 Hysterosalpingogram 500 - 2000 40 4 Hormonal blood assays (FSH, LH, prolactin, estrogen, progesterone) 200-400 10 5 Testicular biopsy 2000 - 10000 200 6 Endometrial biopsy 500 - 2000 400 7 Diagnostic Laparoscopy 10000 -40000 1000 8 Operative Laparoscopy 25000 - 50000 1200 9 Major surgery (microsurgery for tubal repair) 40000 - 65000 1000 10 IUI (insemination) 3000 - 15000 500 11 TID (Therapeutic insemination by donor), per cycle 8000 - 20000 400 12 HMG treatment cycle (for superovulation) 8000 - 20000 400 13 GIFT IN VITRO 50000 - 120000 3500 FERTILIZATION COST 14 IVF 50000 - 120000 3000 15 Embryo freezing 40000 - 80000 3500 16 Microinjection (ICSI) 80000 - 150000 3500 17 Preimplantation genetic diagnosis 150000 - 200000 5000
  9. 9. COST COMPARISON ACROSS GLOBE Cost Comparison NDIA IS MOST The Comparative Costs between India and other developed countries like US, UK, and FAVOURITE AND Singapore - SELECTED Approximate Figures In US Dollars. UK SINGAPO US INDIA (Private) RE upto upto upto1 Bone Marrow Transplant - 200,000 200,000 25,0002 Bypass Surgery 35,000 25,000 - 6,0003 Breast Lump Removal - 3,200 1,000 7004 Haemorrhoidectomy - 3,800 1,500 10005 Knee Joint Replacement - 15,000 7,000 5,0006 Lasik Surgery 4,000 2,800 1,600 7007 No Stitch Cataract Surgery 4,500 2,600 - 7008 In-vitro fertilisation (IVF) cycle 15,000 - - 1,8009 Hernia Correction 2,800 2,700 2,500 1,00010 Dental Implants 3500 2800 1600 800 * These rates are indicative of approximate costs. The actual rates will vary on case to case basis.
  10. 10. DRUGS USUALLY PRESCRIBED IN IVF TREATMENT Sr. No. Generic Name Brand Name 1 Follitropin Alfa Gonal - F (Recombinant FSH) 2 Follitropin Beta Follistim / Puregon ( Recombinant FSH) 3 FSH/Urofollitropin Fostimon / Fertinex/ Bravelle 4 HMG Repronex / Menopur / Merional 5 HCG Pregnyl / Profasi / Novarel 6 Lueproreline/Leuprolide Lupron / Enantone / Procrin (GnRH agonist) 7 Naferelin Acetate Spray Synarel (GnRH agonist) 8 Ganirelix Antagon / Orgalutran (GnRH agonist) 9 Cetrorelix Cetrotide (GnRH agonist) 10 Progesterone Suppositories Prometrium / Cyclogest 11 Progesterone Capsules Prometrium / Utrogestan 12 Progesterone 8% Gel Crinone 13 Progesterone injections Gestone 14 Clomiphene Clomid / Serophene 15 Letrozole Letroz/ Femara 16 Methylprednisolone Medrol / Medrone (steroid) 17 Doxycycline Caps Doxycycline (antibiotic) 18 Estradiol Vvelle / Estraderm / Estradot 19 Estradiol Valerate Progynova/ Estrace / Climaval 20 Desogestrel Desogen / Marvellon (Low dose Birth control pill)
  11. 11. INDIA IVF MARKET OVERVIEWIndia has a large population of 1.22 Billion peopleand infertility in the country is rising at a rapid rate(about 30 Million couples suffer from infertility).Infertility or the inability to have children refers to a range of disorders some of which affect the male, and some the female, and contribute to childlessness in a couple.There is also something called unexplained infertility, where doctors are unable to provide a medical explanation for the couple’s inability to conceive.
  12. 12. INDIA IVF MARKET POTENTIALIn India, approximately 15% - 20% of married couples in their fertile age group,suffer from infertility and it is on the increase because of urbanization, pollution, chemicalexposure, stress, competitive work environment, fast-paced lifestyles, late settlement in life,more women opting to work, increased incidence of diabetes, pelvic inflammatory diseases, etc.Today, arrays of treatment options to treat infertility are readily available in India.These include medications for ovulation induction; endoscopic surgery to correct anatomicalproblems; and the assisted reproductive technologies, including IUI, IVF, and ICSI (intracytoplasmic sperm injection).India has become one of the favored destinations for infertility treatments such as IVF due toseveral factors including its medical expertise, state-of-the-art technology (which is at par withthe best in the world), and a cost-effective health care system.
  13. 13. MARKET SHARE THERAPEUTIC CATEGORY WISE INDIA IVF MARKET Market Share in % 1 Gonadotropins FSH LH 2 HMG ( Human Menopausal Gonadotropins, Menotropins) 3 HCG Sr. No. Therapeutic Category Market Share in % 4 Synthetic GnRH (Gonadotropins Releasing Hormones) 5 GnRH Analogues 1 Gonadotropins FSH LH 10 6 GnRH antagonists 2 HMG ( Human Menopausal Gonadotropins, Menotropins) 15 7 Growth Hormones 3 HCG 9 8 Steroids 4 Synthetic GnRH (Gonadotropins Releasing Hormones) 16 9 Antibiotics 10 Estrogen Antagonists ( Aromatase inhibitors) 5 GnRH Analogues 7 6 GnRH antagonists 5 7 Growth Hormones 12 12% 10% 8 Steroids 6 8% 15% 6% 9 Antibiotics 8 9% 10 Estrogen Antagonists ( Aromatase inhibitors) 12 12% 5% 16% 7%
  14. 14. TOP 10 PLAYERS IN INDIAN IVF SEGMENT MARKET Sun Pharmaceutical Industries Ltd Lupin Pharma Zydus-Cadila Healthcare Ltd Intas Pharmaceuticals Ltd CIPLA Emecure House Bharat Serums and Vaccines Ltd Uni-Sankyo Limited Serum Institute of India Alembic LimitedOther Emerging Players are: Lifemedicare Svizera Laboratories Private Limited VHB Life Sciences Inc Plethico Pharmaceuticals Limited Ferring BV
  15. 15. SUN PHARMA IVF SEGMENT MARKET LEADER IN INDIAFamous Brands of SUN Pharmaceutical LTD :1. leuprolide acetate : Brand Name : LUPRIDE Dosage Form : Injectable Strengths available : 1 mg/ 4 mg/ 11.2 mg/3.75 mg/22.5 mg2. Gonadotropin chorionic Brand Name : FERTIGYN Dosage Form : Injectable Strengths available : 1000/2000/5000 IU in Ampoules 10000 IU in Vials3. Follitropin beta Brand Name : OVITROP-R Dosage Form : Injectable Strengths available : 1.20 ml/1.60 ml/0.40 ml4. Letrozole : Brand Name : LETOVAL / LETROZ Dosage Form : Tablets Strengths available : 2.5 mg
  16. 16. MONOPLOY OF PLAYERS IN SOME THERAPEUTIC CATEGORY IN INDIA IVF MARKET1. For Cetrorelix acetate Injectable : only 1 Player in India Market CISCURE by EMECURE2. For Choriogonadotropin alfa Molecule in India only 2 Players (OVITRELLE ) Merck KGaA & (PUBERGEN-HP ) UNI SANKYO3. For Follitropin beta : only 3 Players ( OVITROP-R ) by Sun Pharma ( RECAGON ) by ORGANON ( PUREGON-R ) by ABOTT4. For Letrozole, leuprolide acetate, urofollitropin, gonadotropin chorionic more than 25 players are present in Domestic Market
  17. 17. REGULATORY ASPECTS INDIATHE ASSISTED REPRODUCTIVE TECHNOLOGIES (REGULATION) BILL – 2010MINISTRY OF HEALTH & FAMILY WELFARE , GOVT. OF INDIA, NEW DELHIINDIAN COUNCIL OF MEDICAL RESEARCH , NEW DELHICHAPTER – II 5-11CONSTITUTION OF AUTHORITIES TO REGULATE ASSISTEDREPRODUCTIVE TECHNOLOGIE3. Establishment of National Advisory Board 54. Meetings of National Advisory Board 5-65. Functions of National Advisory Board 66. Establishment of State Boards 77. Meetings of State Boards 78. Powers and functions of State Boards 89. Term of office, conditions of service, etc., of Chairperson 8-9and other members of State Boards10. Procedure of State Boards 9-1011 Constitution and functions of the Registration Authority 1012. Proceedings before State Boards to be judicial proceedings 10-11
  18. 18. THE ASSISTED REPRODUCTIVE TECHNOLOGIES (REGULATION) BILL – 2010 CHAPTER – III 12-14 PROCEDURES FOR REGISTRATION AND COMPLAINTS 13. Registration and accreditation of clinics 12 14. Who may apply for registration 13 15. Grant of registration 13 16. Renewal, suspension or revocation of registration 14 CHAPTER – V 20-22 17. Registration Authority to inspect premises 14 SOURCING, STORAGE, HANDLING AND 18. Applicability to ART banks and research organizations 14 RECORD KEEPING FOR 19. Appeal to the State Board 14 GAMETES, EMBRYOS AND SURROGATES CHAPTER – IV 15-19 26. Sourcing of gametes 20-21 DUTIES OF AN ASSISTED REPRODUCTIVE TECHNOLOGY CLINIC 20. General duties of assisted reproductive technology clinics 15-17 27. Storage and handling of gametes and embryos 21 21. Duty of the assisted reproductive technology clinic to 17 obtain written consent 28. Records to be maintained by the ART 22. Duty of the assisted reproductive technology clinic to keep 17-18 bank 22 accurate records 29. Restriction on sale of 23. Duties of assisted reproductive technology clinics using 18 gametes, zygotes and embryos 22 gametes and embryos 24. Pre-implantation Genetic Diagnosis 19 25. Sex selection 19
  19. 19. THE ASSISTED REPRODUCTIVE TECHNOLOGIES (REGULATION) BILL – 2010 CHAPTER – VIII 30-32CHAPTER – VI 23-24 OFFENCES AND PENALTIESREGULATION OF RESEARCH ON EMBRYOS, GAMETES OR 37. Prohibition of advertisement relating to pre-natal determination 30OTHER of sex and punishment for contraventionHUMAN REPRODUCTIVE MATERIAL 38. Offences and penalties 30-3130. Permission of the Department of Health Research for 39. Presumption in the case of conduct of pre-natal diagnostic 31research 23 techniques31. Regulation of research 23-24 40. Penalty for contravention of the provisions of the Act or rules 31 for which no specific punishment is provided 41. Offences by companies 31-32 42. Offence to be cognizable 32CHAPTER – VII 25-29 CHAPTER – IX 33-35RIGHTS AND DUTIES OF PATIENTS, DONORS, SURROGATES AND MISCELLANEOUSCHILDREN 43. Maintenance of records 3332. Rights and duties of patients 25 44. Power to search and seize records etc. 3333. Rights and duties of donors 25 45. Power to remove difficulties 3334. Rights and duties in relation to surrogacy 26-28 46. Protection of action taken in good faith 3435. Determination of status of the child 28-29 47. Power to make regulations 3436. Right of the child to information about donors or surrogates 48. Power of the Central Government to make rules 34-3529 49. Power of State Government to make rules 35 50. Act to have effect in addition to other Acts 35
  20. 20. REGULATORY ASPECTS WORLD WIDE
  21. 21. REGULATORY ASPECTS WORLD WIDE
  22. 22. TEAM SELECTION AND FACTOR AFFECTING• TEAM SELECTION IS MOST IMPORTANT FACTOR FOR MARKETING STRATEGY FOR ANY PHARMACEUTICAL COMPANY,• For Product Management Team : its important to update the data about the clinics For infertility treatment and other diagnostics /blood testing procedures while Each IVF Cycles ,advances in technology for the same• Also understanding the IVF Procedure and the medication dosage regimen during entire process is another critical aspect.• Understanding Short term long term protocol for IVF Procedures ,• As on date there are more than 20,000 Infertility clinics in India and Majority are in Mumbai , at 2nd place Bangalore and at 3rd place Delhi is there in India .• There are more than 15,000 Doctors /Surgeons are included in this market• Apart from medical teams , in India some clinics provide total package for foreign visitors from the day of beginning to end of the treatment .• Team selection should be based on the factors mentioned in other slide
  23. 23. THE FACTORS AFFECTING TEAM SELECTION FOR IVF MARKET1. Competitive Landscape in same region/ state2. Understanding of Unorganized & Fragmented Market3. Understanding India Total Fertility Rate Profile4. Updates about merging In Vitro Fertilization (IVF) Market Trends5. Awareness about India Fertility Tourism6. Updating Technological Advances in Treatment Procedures7. Considering Changing Lifestyle Effecting Fertility Profile Among Youngsters8. Infertility Rate Among Indian Couples9. Awareness about Investment & Foreign Collaboration of Indian players
  24. 24. RECOMMENDATION & SUGGESTIONSThe most important economic issues in contemporary ART markets are:1) Access to treatment2) Treatment success, as measured through birth rates and multiple birth rates.These issues of access and quality are also the central concerns for Indian health care markets ingeneral.• Across the medical sector of the economy and in IVF markets in particular,it has been suggested that altering the competitive structure of markets or the extent ofinsurance coverage can improve both access to care and quality.• In the market for infertility treatment, mandatory insurance coverage is predicted to bring new patients into the market and reduce the incentive to transfer a dangerously high number of embryos during treatment, thereby increasing the quality of care.• While price reducing competition is likely to improve access to IVF, there exist concerns thatcompeting clinics will attempt to win new patients by inflating birthrates using treatments thatalso raise the risk of multiple births.
  25. 25. RECOMMENDATION & SUGGESTIONS• However, concerns about quality-reducing competition may be incorrect, and in fact additional competition can decrease multiple birth rates by reducing patients’ incentive to seek aggressive treatment for their fertility problems. With the present paper we evaluate the impacts of both mandated insurance coverage and an increase in competition on ART access and treatment success rates.• We expect the use of IVF to continue to grow, as treatment expenses fall with competition and technological progress, and more women account for the possibility of ART while making related life cycle choices regarding education, career, and marriage.• Indeed, the changing economic environment of the late 21st century is likely to have shifted substantially the demand for infertility treatment services.• As women’s labor force participation rates and real wages have increased, couples have deferred the decision to have children
  26. 26. RECENT UPDATES/ REASERCH IN WORLD IVF MARKET• Cooper To Lead In Vitro Fertilization Market Following $189 Million Origio Acquisition ,Deal will boost Cooper’s share of the $220 million global IVF market from 7% to 39%.• Discovery of a Molecule That Initiates Maturation of Mammalian Eggs Can Lead to More IVF Pregnancies researchers at the University of Gothenburg have identified a molecule called Cdk1 that has an important function for mammalian egg maturation. In the future this could lead to an increased rate of successful IVF.This is the first functional evidence that Cdk1 is a key molecule in mammalian egg maturation. If the results can be translated into clinical settings, it could possibly improve the chances of successful IVF treatment for women who today are not becoming pregnant because their eggs do not mature" says Kui Liu, professor at the Department of Chemistry and Molecular Biology, the University of Gothenburg, Sweden.
  27. 27. RESEARCH IN WORLD IVF MARKET• A new technique successfully used in mice to identify embryos likely to result in a successful pregnancy could be used in humans, according to University scientists. The Cardiff scientists worked with a team in Oxford University to analyse the internal contents of the human egg or cytoplasm to observe distinct rhythmic patterns."Current IVF treatment involves fertilising eggs in the laboratory and then choosing those embryos considered to be the healthiest for implantation into the mothers womb, using selection criteria such as the number and appearance of cells produced during the division process," according to Professor Karl Swann, School of Medicine, who led the research.• New Method for Picking the Right Egg in IVF:• groundbreaking study,Yale School of Medicine researchers and colleagues at the University of Oxford have identified the chromosomal make-up of a human egg. This discovery may soon allow them to avoid using abnormal -- or aneuploid -- eggs during infertility treatments, and instead to pick eggs that are healthy enough for a successful in vitro fertilization (IVF) cycle.• "This finding opens up the possibility of a safe, effective, and inexpensive way of identifying healthy eggs, potentially lowering the risks of miscarriage and Down syndrome," said Wells. "By conducting these tests before eggs are fertilized, ethical concerns about analysis of human embryos are avoided."
  28. 28. FUTURE OF INFERTILITY TRATMENTThe development of techniques to prolong the window of fertility for women has the ability to meet the needs of future populations and their delay in childbearing.With current techniques of cryopreservation of embryos, oocytes, or ovarian tissue, prolongation of fertility with varying success is feasible.In the future, rejuvenation of aging oocytes will offer the opportunity for the aging women to achieve pregnancy with their own genetic offspring.Production of germ cells from embryonic stem cells is another alternative for patient with poor or depleted germ cells.Better understanding of the cause of infertility can be achieved with new techniques to evaluate the oocytes, spermatozoa, and embryos on molecular and genetic levels.With improved understanding of the etiology of infertility, treatment will be more effective.With the advance of new drugs and surgical equipment, treatment of infertility will become more convenient and effective.
  29. 29. UPCOMING CONFERENCES - INDIAIndian Society for the Study of Reproduction and Fertility (ISSRF)The 23rd Annual Meeting of the ISSRF along with an International Conference on Repromics- Omics in Reproduction and Development will be held at the Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram during February 7-9, 2013. The relevant information will be up-loaded from time to time and will be circulated to all members of the Society. The contact person is: Dr. Pradeep Kumar G Scientist F Rajiv Gandhi Centre for Biotechnology Thycaud Post, Poojappura Thiruvananthapuram - 695014, Kerala, India Tel.: +91-471-2529459 E-mail: kumarp@rgcb.res.in
  30. 30. UPCOMING CONFERENCES - INDIA8th Annual National Conference of Indian Fertility Society on "INFERTILITY & ASSISTED REPRODUCTIVE TECHNOLOGIES" 8th & 9th December, 2012 ( 13 Dec, 2012 )
  31. 31. UPCOMING CONFERENCES - INDIAConference Name : Amasicon2006:Date & Venue : March 31st April 1st & 2nd Kolkata, Hotel Hyatt Regency-Venue,Contact Address : ILS MultispecialityClinic-Surgery, Jeewansatya, DD-6, Sector 1,Salt Lake City, Kolkota, West Bengal Pin:700064Office & Mobile Phone : Office: +91-33-23593700, Mobile: +91-9830400300, Telefax: +91-33-23214912Email & Web : Email: secreteriat@amasicon2006.com Web: www.amasicon2006.com
  32. 32. UPCOMING INTERNATIONAL CONFERENCES - INTERNATIONAL2012-06-13International Society for Stem Cell Research 10th Annual Meeting Dates: June 13-16. 2012 Location: Pacifico Yokohama, Yokohama, JAPAN For more information: http://www.isscr.org 2012-06-162012 AMA Annual Assembly Meeting Dates: June 16-20, 2012 Location: Chicago, IL, USA For More Information:http://www.ama-assn.org2012-06-20Society of Obstetricians and Gynaecologists of Canada 68th Annual Clinical Meeting Dates: June 20-24, 2012 Location: Ottawa, Ontario, CANADA For more information: http://www.sogc.org 2012-06-23ENDO 2012 Sponsor: The Endocrine Society Dates: June 23-26, 2012 Location: Houston, Texas, USA For more information: http://www.endo-society.org 2012-06-278th International Congress on Minimally Invasive Gynecology Sponsors: American Association of Gynecologic Laparoscopists and the Romanian Society of Minimally Invasive Surgery in Gynecology Dates: June 27 - July 1, 2012 Location: Bucharest, ROMANIA For more information: http://www.aagl.org 2012-07-01ESHRE 2012 Description: 28th Annual Meeting of the European Society of Human Reproduction and Embryology Dates: July 1-4, 2012 Location: Istanbul, TURKEY For More Information:http://www.eshre.eu
  33. 33. UPCOMING INTERNATIONAL CONFERENCES - INTERNATIONALInternational Academy of Sex Research 38th Annual Meeting Dates: July 8-11, 2012 Location: Lisbon, PORTUGAL For more information: http://www.iasr.org 2012-07-26North American Council on Adoptable Children 38th Annual Conference Dates: July 26–28, 2012 Location: Crystal City, Virginia, USA For more information: https://www.nacac.org/conference/conference.html 2012-08-0212th Asia-Oceania Federation of Sexology (AOFS) Meeting Dates: August 2-5, 2012 Location: Matsue, JAPAN For more information: http://www.12aocs.jp 2012-08-1245th Annual Meeting of the Society for the Study of Reproduction Theme: “Applied Reproductive Biology: Making It Relevant” Dates: August 12–15, 2012 Location: The College of Agricultural Sciences, The Pennsylvania State University, State College, Pennsylvania, USA For more information: http://www.ssr.org 2012-08-2211th Asian Congress of Urology Sponsor: The Urological Association of Asia Dates: August 22-26, 2012 Location: Pattaya, THAILAND For more information: http://11thacu2012.org 2012-08-26
  34. 34. UPCOMING INTERNATIONAL CONFERENCES - INTERNATIONALSMSNA/ISSM Joint Annual Meeting Sponsor: Sexual Medicine Society of North America Dates: August 26-30, 2012 Location: Sheraton Chicago Hotel & Towers, Chicago, IL, USA For More Information: http://www.smsna.org2012-09-0521st SLS Annual Meeting and Endo Expo 2012 Sponsor: Society of Laparoendoscopic Surgeons Dates: September 5-8, 2012 Location: Westin Copley Place, Boston, MA, USA For More Information: www.sls.org2012-09-06CFAS 2012 Sponsor: Canadian Fertility and Andrology Society Dates: September 6-9, 2012 Location: Ottawa Westin, Ottawa, Ontario, CANADA For More Information: www.cfas.ca2012-10-20ASRM 2012 Description: 68th Annual Meeting of the ASRM Dates: October 20-24, 2012 Place: San Diego Convention Center, San Diego, California, USA For More Information: ASRM, Tel: 205-978-5000, Fax: 205-978-5018, Email: asrm@asrm.org
  35. 35. UPCOMING INTERNATIONAL CONFERENCES - INTERNATIONAL2012-12-06 (ESSM)15th Congress of the European Society for Sexual Medicine (ESSM) Dates: December 6-9, 2012 Location: Amsterdam, THE NETHERLANDS For more information: http://www.essm.org 2013-03-07The Best of ESHRE & ASRM Dates: March 7-9, 2013 Location: Atlantis, Paradise Island, BAHAMAS For more information: http://www.asrm.org/Atlantis2013/ 2013-04-172013 Pacific Coast Reproductive Society Annual Meeting Dates: April 17-21, 2013 Location: Renaissance Esmeralda, Indian Wells, CA, USA For More Information: http://www.pcrsonline.org2013-05-042013 ACOG Annual Clinical Meeting Dates: May 4-8, 2013 Location: New Orleans, LA, USA For More Information: http://www.acog.org/2013-06-152013 AMA Annual Assembly Meeting Dates: June 15-19, 2013 Location: Chicago, IL, USA For More Information: http://www.ama-assn.org2013-10-12Joint ASRM/IFFS Meeting Description: 69th Annual Meeting of the ASRM held conjointly with the Meeting of the International Federation of Fertility Societies Dates: October 12-17, 2013 Place: Boston Convention and Exhibition Center, Boston, MA, USA For More Information: ASRM, Tel: 205-978-5000, Fax: 205-978-5018, Email: asrm@asrm.org: Website: http://www.asrm.org/IFFS-ASRM2013/2014-04-232014 Pacific Coast Reproductive Society Annual Meeting Dates: April 23-27, 2014 Location: Renaissance Esmeralda, Indian Wells, CA, USA For More Information: http://www.pcrsonline.org
  36. 36. UPCOMING INTERNATIONAL CONFERENCES - INTERNATIONAL2014-06-072014 AMA Annual Assembly Meeting Dates: June 7-11, 2014 Location: Chicago, IL, USA For More Information: http://www.ama-assn.org2014-10-18ASRM 2014 Description: 70th Annual Meeting of the ASRM Dates: October 18-22, 2014 Place: Hawaii Convention Center, Honolulu, HI, USA For More Information: ASRM, Tel: 205-978-5000, Fax: 205-978-5018, Email: asrm@asrm.org2015-06-062015 AMA Annual Assembly Meeting Dates: June 6-10, 2015 Location: Chicago, IL, USA For More Information: http://www.ama-assn.org2015-10-17ASRM 2015 Description: 71st Annual Meeting of the ASRM Dates: October 17-21, 2015 Place: Baltimore Convention Center, Baltimore, MD, USA For More Information: ASRM, Tel: 205-978-5000, Fax: 205-978-5018, Email: asrm@asrm.org2016-06-112016 AMA Annual Assembly Meeting Dates: June 11-15, 2016 Location: Chicago, IL, USA For More Information:http://www.ama-assn.org
  37. 37. THANK YOU

×